

# Empagliflozin for No-reflow Phenomenon in PCI for STEMI

NCT06342141

---

Status	RECRUITING
Phase	Phase 2
Sponsor	Instituto Nacional de Cardiologia Ignacio Chavez
Enrollment	162 participants

## Key Eligibility Criteria

---

### Inclusion (5)

- Acute myocardial infarction with ST-segment elevation
- Presentation to the institute within 12 hours of symptom onset
- Coronary angioplasty chosen as the reperfusion treatment for the subject
- Known diagnosis of diabetes or admission glucose  $>180$  mg/dl.
- Informed consent signed

### Exclusion (9)

- Hemodynamically unstable subjects
- Subjects undergoing thrombolysis treatment in the current event
- History of coronary revascularization surgery
- Known allergy or hypersensitivity to Sodium-glucose co-transporter-2 (SGLT2) inhibitors
- History of recurrent urinary tract infections
- ... and 4 more (see full listing online)

## Locations (1 total)

---

National Institute of Cardiology, Mexico City, Mexico City, Mexico